Xeljanz by Pfizer: The Next Massive Lawsuit in the U.S.A.

Comments · 298 Views

https://www.lezdotechmed.com/blog/mass-tort/pfizer's-xeljanz/
Because of safety concerns, the FDA has previously placed limitations on the use of Pfizer's Xeljanz at a higher dosage.

https://www.lezdotechmed.com/blog/mass-tort/pfizer's-xeljanz/

The Food and Drug Administration (FDA) has approved Pfizer's Xeljanz (tofacitinib) and Xeljanz XR to treat the following diseases: Ankylosing spondylitis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis.

Some of the serious side effects of Pfizer's Xeljanz and Xeljanz XR include: plasma problems, heart attack or stroke, cancer risks, immune system disorders, and death in some people. Tears in the intestine, risk of serious infections, blood clot

The Food and Drug Administration issued new warnings on July 26, 2019, regarding an increased risk with the 10 mg twice daily dose of Xeljanz and Xeljanz XR. The FDA issued an updated medication safety advisory for Xeljanz in September 2021. According to the warning, Xeljanz, at any dosage level, increases the risk of serious heart problems such as heart attacks and strokes, cancer, blood clots, and death in patients receiving both doses of the medication. Xeljanz received the FDA's most critical "black box" warning on December 2, 2021. According to the FDA's newly updated warnings, prescribers are strongly advised to use TNF blockers instead of Xeljanz to treat ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis.

There haven't been many legal actions filed against Pfizer because the warnings about the possibility of Xeljanz tofacitinib side effects were only recently revealed. There is no multidistrict litigation class action as of February 2022. However, as more people become aware of Xeljanz's negative side effects, this may change. A product liability lawsuit may also be filed against Xeljanz.

The first step in filing a mass tort action against pharmaceutical companies is gathering and combining multiple cases in federal court. The process is known as Multi-District Litigation (MDL), but it has not yet been used in the Xeljanz cases. All of the Xeljanz lawsuits are currently in court.

Xeljanz by Pfizer is not the first arthritis medication to face multiple lawsuits. Pfizer had previously been acquitted in 2005 for the drugs Bextra and Celebrex. Approximately 1,200 plaintiffs have filed a personal injury or wrongful death lawsuit against Pfizer, requesting that Bextra and Celebrex be taken off the market because they increase the risk of heart attacks.

It is critical to file a lawsuit against the manufacturer of the drug that is causing severe side effects for you or your loved ones, but going up against a pharmaceutical company is not easy. You must make certain that your  medical record is free of errors. As a result of your Pfizer's Xeljanz lawsuit, your complaint will be elevated, and you will be compensated more fairly.

xeljanztofacitinib

xeljanz2022

 newxeljanzwarning

 isthereagenericformofxeljanz

xeljanzlatestnews

 lawsuitagainstxeljanz

Comments
ADVERTISE || APPLICATION || AFFILIATE